#ECFS2018 – Phase 2 Trial Supporting SPX-101 as Treatment for All with CF, Spyryx CMO Says

SPX-101, designed to help clear mucus from the lungs of people with cystic fibrosis, has the potential to treat all CF patients — regardless of disease-causing mutations. The experimental peptide, which blocks the overactive sodium channels that line CF lung cells so more fluids are retained on airway surfaces to hydrate mucus,…

Spyryx Names Alistair Wheeler Its CMO, Will Lead Testing of CF Therapy

Spyryx Biosciences recently announced that Dr. Alistair Wheeler is joining the company as its new chief medical officer. Spyryx, a clinical-stage biopharma specializing in therapeutics for respiratory diseases, is currently evaluating a potential treatment for cystic fibrosis (CF) in early clinical testing. Wheeler will be responsible for all aspects of clinical and medical processes and associated regulatory…